GLP-1s like Ozempic are among the most important drug breakthroughs ever
Their far-reaching potential could transform how chronic diseases are managed
IN THE HISTORY of medicine, a few drugs tower above all others. Humira for rheumatoid arthritis; Prozac for depression; statins to prevent heart disease and strokes. All have helped patients far beyond doctors’ initial expectations and continue to benefit millions of people every day. A new class of drugs is set to join their ranks and has the potential to eclipse them all—GLP-1 receptor agonists.
This article appeared in the Briefing section of the print edition under the headline “One jab to treat them all”
From the October 26th 2024 edition
Discover stories from this section and more in the list of contents
Explore the editionDiscover more
How will Donald Trump handle the war in Ukraine?
And how will Ukraine, Russia and Europe respond?
Elon Musk’s transformation, in his own words
Our analysis of 38,000 posts on X reveal a changed man
Elon Musk and Donald Trump seem besotted. Where is their bromance headed?
The precedents are not encouraging
The energy transition will be much cheaper than you think
Most analysts overestimate energy demand and underestimate technological advances
Donald Trump’s victory was resounding. His second term will be, too
Congress is not likely to be much of a constraint on him
How bad could a second Trump presidency get?
The damage to America’s economy, institutions and the world would be huge